Aidoc wins FDA breakthrough designation for AI-assisted chest X-ray reading. CroiValve adds $27 million to its Series B to expand the TANDEM II trial. Medtronic launches the MiniMed Instinct glucose sensor in Europe. Neurobell, a Cork startup, closes a $5.5 million seed round to commercialize its AI neonatal EEG monitor in the US.
Top Stories
Lead Story
Story 01
Aidoc has secured FDA 510(k) clearance for its AI-powered chest X-ray triage system, designed to help hospital radiologists prioritize critical findings in real time. The system analyzes chest radiographs and flags abnormalities including pneumothorax, pulmonary embolism, and intracranial hemorrhage, allowing radiologists to address time-sensitive diagnoses faster. The breakthrough device designation accelerates FDA review for technologies that address life-threatening conditions.
Aidoc has deployed its AI radiology platform across more than 150 health systems globally, covering over 1 million AI-assisted CT reads. This clearance marks a meaningful expansion of its existing portfolio, which already includes FDA-cleared AI tools for brain hemorrhage, spine fracture, and pulmonary embolism detection. The chest X-ray module integrates into existing radiology workflows without requiring additional hardware or workflow changes.
Why It Matters
Hospital radiology departments face mounting pressure to reduce report turnaround times while maintaining accuracy across high volumes of imaging studies. AI triage that surfaces critical findings first does not replace radiologist judgment; it changes the order in which cases are reviewed. Aidoc's expansion from neuro-CT into chest X-ray leverages an installed base of 150+ health systems who can adopt the chest module without a new procurement cycle, creating a compounding distribution advantage as radiology AI markets become more crowded.
AI
FDA
Radiology
Story 02
Irish medtech company CroiValve has announced a $27 million expansion of its Series B financing to support an enlarged TANDEM II clinical trial for its DuoAdapt transcatheter tricuspid regurgitation system. The announcement follows an earlier Series B close and brings total Series B funding to a figure the company described as material to its near-term regulatory timeline. CroiValve is targeting both FDA and CE Mark submissions based on the TANDEM II data set.
The DuoAdapt system is a transcatheter device designed to repair the tricuspid valve by implanting a bicomposite support structure that reduces valve annulus diameter and restores leaflet coaptation. Unlike surgical tricuspid repair, the DuoAdapt procedure is performed transvenously without cardiopulmonary bypass, making it an option for patients who are poor candidates for open heart surgery. The TANDEM II study is currently enrolling at clinical sites in the United States and Ireland.
Why It Matters
Approximately 1.6 million Americans have moderate or severe tricuspid regurgitation, and fewer than 5% ever receive surgical intervention. A transcatheter option with a favorable safety profile could open a treatment pathway for hundreds of thousands of patients who currently have none. CroiValve's funding ensures the TANDEM II expansion proceeds without financial constraint, keeping the company on track for regulatory submissions in the United States and Europe.
Cardio
Funding
Regulatory
Story 03
Medtronic has launched its MiniMed Instinct continuous glucose monitoring sensor in European markets following regulatory approval. Developed in partnership with Abbott, the sensor integrates with the MiniMed 780G automated insulin delivery system, adding a sensing layer to Medtronic's 900,000-user pump ecosystem. The 780G system uses CGM data to adjust insulin delivery automatically, reducing the manual dosing burden for type 1 diabetes patients.
Why It Matters
The CGM market has become one of the most contested spaces in MedTech, with Dexcom and Abbott competing aggressively for market share and health system adoption. With MiniMed Instinct now commercially available in Europe, Medtronic can offer its existing 900,000 pump users a sensor upgrade that keeps them within the Medtronic ecosystem rather than switching to a competing pump platform with better-integrated CGM.
Digital Health
Regulatory
Competition
Story 04
Cork-based medtech startup Neurobell has raised $5.5 million in seed funding to support the US commercialization and further development of Luna, its AI-powered continuous EEG monitoring system for neonatal intensive care units. The funding round was led by a group of angel investors with expertise in medical devices and digital health. Neurobell expects to use the proceeds to establish US commercial operations and build out its clinical affairs team.
Why It Matters
Neonatal seizures are frequently subtle and easily missed by clinical staff, yet untreated seizures can cause permanent neurological injury within minutes. Continuous EEG monitoring addresses that gap, but adoption in NICUs has been limited by the need for specialized neurology expertise to interpret the data. Neurobell's AI interpretative engine solves that bottleneck by flagging seizure activity and brain oxygenation patterns in real time for NICU clinical staff.
The US NICU market is substantial: approximately 1 in 7 infants in the United States is admitted to a NICU each year, and the patient population includes a high proportion of premature infants and those with neurological risk factors. Luna's FDA clearance positions Neurobell to address an unmet clinical need in that setting with a device that requires minimal specialized training to operate.
AI
Neonatal
Funding
The Signal
The common thread across this week's four stories is the spectrum of company maturity in the MedTech market: Aidoc is adding a fifth AI radiology module to an installed base of 150 health systems; CroiValve is generating pivotal trial data ahead of regulatory submissions; Medtronic is adding a sensing layer to its existing diabetes ecosystem; and Neurobell is preparing its first US commercial launch. Four companies, four different chapters. That diversity is the signal.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $475.20 | ▼ 0.2% |
| SYK | Stryker | $307.80 | ▲ 0.2% |
| MDT ★ | Medtronic | $81.90 | ▲ 1.6% |
| BDX | Becton Dickinson | $240.10 | ▲ 0.1% |
| ABT | Abbott | $118.40 | ▲ 0.2% |
| GEHC | GE HealthCare | $87.50 | ▲ 0.2% |
| EW | Edwards Lifesciences | $83.50 | ▼ 0.2% |
| BSX | Boston Scientific | $80.90 | ▲ 0.1% |
★ Biggest Mover: Medtronic (MDT) gained 1.6% on news that MiniMed Instinct launched in European markets, adding a CGM sensing layer to its 900,000-user insulin pump ecosystem and reinforcing its competitive position against Dexcom in the glucose monitoring space. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of June 29, 2026. For illustrative purposes only.
⏳ That's your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact
Aidoc's AI radiology platform has been deployed across more than 150 health systems globally, covering over 1 million AI-assisted CT reads across brain, spine, pulmonary, and now chest imaging. CroiValve is also notable as the only medtech company running a pivotal FDA trial for a transcatheter tricuspid repair system with an Irish management team and a manufacturing base in Galway, Ireland.
Trivia
MedTech Trivia
Aidoc now has FDA clearances covering five distinct AI radiology modules across neurology, spine, pulmonary, and chest imaging. What competitive advantage does an installed base of 150 health systems represent when deploying each new AI module to existing customers versus acquiring new health system customers from scratch?
If you're building, hiring, or investing in MedTech, reply and tell me what you're seeing. I read every response.
